LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)Naveen Vasudev, T.B. Powles, Sarah Brown et al.|Annals of Oncology|2021Cited by 9